Alzheimer's disease

Biohaven Provides Update On Phase 2/3 Trial And Alzheimer's Disease Program
Biohaven Provides Update On Phase 2/3 Trial And Alzheimer's Disease Program
BioSpace
Biohaven
Alzheimer's disease
clinical trials
troriluzole
Flag link:
Here's the Top FDA Decision to Watch in 2021
Here's the Top FDA Decision to Watch in 2021
Motley Fool
FDA
Biogen
aducanumab
Alzheimer's disease
Flag link:
Could Lilly’s donanemab readout in Alzheimer’s boost Biogen’s prospects?
Could Lilly’s donanemab readout in Alzheimer’s boost Biogen’s prospects?
Pharmaforum
Eli Lilly
Alzheimer's disease
clinical trials
donanemab
Flag link:
Lilly rockets up on mixed Alzheimer's results
Lilly rockets up on mixed Alzheimer's results
BioPharma Dive
Eli Lilly
Alzheimer's disease
clinical trials
donanemab
Flag link:
3 FDA Dates Biotech Investors Should Circle in 2021
3 FDA Dates Biotech Investors Should Circle in 2021
Motley Fool
FDA
biotech
Bluebird Bio
ide-cel
Multiple Myeloma
Biogen
aducanumab
Alzheimer's disease
targeted therapeutics
umbralisib
maringal zone lymphoma
Flag link:
Novo takes the plunge in Alzheimer’s
Novo takes the plunge in Alzheimer’s
EP Vantage
Novo Nordisk
Rybelsus
Alzheimer's disease
Flag link:
Second Shot at Alzheimer's Proves Unsuccessful for vTv Therapeutics' Azeliragon
Second Shot at Alzheimer's Proves Unsuccessful for vTv Therapeutics' Azeliragon
BioSpace
vTv Therapeutics
azeliragon
Alzheimer's disease
Flag link:
Public Citizen Demands Investigation into "Inappropriate Collaboration" Between FDA and Biogen Over Alzheimer's Drug
Public Citizen Demands Investigation into "Inappropriate Collaboration" Between FDA and Biogen Over Alzheimer's Drug
BioSpace
Biogen
OIG
HHS
aducanumab
Public Citizen
Alzheimer's disease
Flag link:
Research Alzheimer's discovery generates novel drug candidate for early intervention
Research Alzheimer's discovery generates novel drug candidate for early intervention
Fierce Biotech
Alzheimer's disease
Case Western Reserve
Flag link:
Eli Lilly Designs P-Tau Biomarker Assay for Early Alzheimer’s Disease Diagnosis
Eli Lilly Designs P-Tau Biomarker Assay for Early Alzheimer’s Disease Diagnosis
BioSpace
Eli Lilly
Alzheimer's disease
biomarker assays
biomarkers
diagnostics
P-tau
Flag link:
Biogen ‘continues to work’ with FDA on Alzheimer's drug candidate despite regulatory setback
Biogen ‘continues to work’ with FDA on Alzheimer's drug candidate despite regulatory setback
Biopharma Reporter
Biogen
FDA
Alzheimer's disease
aducanumab
Flag link:
5 takeaways from the FDA's high-stakes meeting for Biogen's Alzheimer's drug
5 takeaways from the FDA's high-stakes meeting for Biogen's Alzheimer's drug
BioPharma Dive
Biogen
FDA
Alzheimer's disease
aducanumab
clinical trials
amyloid
Flag link:
Why Biogen Stock Is Tanking Today
Why Biogen Stock Is Tanking Today
Motley Fool
Biogen
aducanumab
FDA
Alzheimer's disease
Flag link:
FDA advisers vote against Biogen's Alzheimer's drug, leaving its future in doubt
FDA advisers vote against Biogen's Alzheimer's drug, leaving its future in doubt
Biopharma Dive
Biogen
aducanumab
FDA
advisory panels
Alzheimer's disease
Flag link:
The FDA's insider review on aducanumab was all about politics, not science, and it threatens patients and the biopharma industry alike
The FDA's insider review on aducanumab was all about politics, not science, and it threatens patients and the biopharma industry alike
Endpoints
FDA
Biogen
aducanumab
Alzheimer's disease
Flag link:
FDA scientists appear to offer major endorsement of Biogen’s controversial Alzheimer’s treatment
FDA scientists appear to offer major endorsement of Biogen’s controversial Alzheimer’s treatment
Stat
Biogen
aducanumab
Alzheimer's disease
FDA
advisory panels
Flag link:
The meeting that could change Alzheimer's treatment
The meeting that could change Alzheimer's treatment
BioSpace
Biogen
aducanumab
Alzheimer's disease
FDA
Flag link:
Biogen's reprieve as critic recused from aducanumab panel, but analysts still read rejection in the tea leaves
Biogen's reprieve as critic recused from aducanumab panel, but analysts still read rejection in the tea leaves
Fierce Biotech
Biogen
aducanumab
FDA
advisory panel
Alzheimer's disease
Flag link:
Neuraly gets FDA clearance of INDA to initiate phase 2b trial of NLY01 in Alzheimer’s Disease
Neuraly gets FDA clearance of INDA to initiate phase 2b trial of NLY01 in Alzheimer’s Disease
Pharmaceutical Business Review
Neuraly
NLY01
clinical trials
Alzheimer's disease
Flag link:
Aducanumab’s day of reckoning approaches
Aducanumab’s day of reckoning approaches
EP Vantage
Biogen
earnings
aducanumab
FDA
Alzheimer's disease
Flag link:

Pages